Gilead price target raised to $157 from $155 at Truist

Truist raised the firm’s price target on Gilead (GILD) to $157 from $155 and keeps a Buy rating on the shares. The company delivered Q1 top- and bottom-line beats with a raised FY26 revenue guide, driven by HIV strength, particularly Yeztugo, the analyst tells investors in a research note. The firm further underscores the commentary around early persistency signals – including Yeztugo being the highest among patients receiving re-treatment in the PrEP setting – as encouraging and central to its thesis for durable Yeztugo growth toward our $7B+ peak revenue opportunity.